Shortly after going ahead and securing a partnership with Sanofi, InduPro is now linking up with Eli Lilly in its endeavors to discover novel cancer treatments through a pact that could as well be worth almost $950 million.
InduPro is going to work with the Big Pharma company on around three undisclosed cancer targets, as per a January 6, 2026 release.
As per the terms of the deal, InduPro could as well collect almost $950 million, with Lilly also going ahead and making an equity investment of an amount in the company that isn’t disclosed.
Notably, InduPro is going to lead the early discovery efforts through using its artificial intelligence – machine learning – AI/ML enabled membrane interactomics – MInt platform.
InduPro, which is headquartered in both Seattle and Cambridge, Massachusetts, looks forward to creating both bi- and tri-specific therapeutics when it comes to discover novel cancer treatments and autoimmune diseases. Started in 2022, the platform from the biotech firm goes on to analyze how close the tumor antigens happen to be to each other in their push to discover the disease-specific protein-target pairs.
The company goes on to believe that its approach could very well help in developing bispecific antibody-drug conjugates along with multispecific T-cell engagers having better safety and potency as well as tumor selectivity properties.
According to Prakash Raman, Ph.D., CEO of InduPro, their partnership with Lilly highlights a shared commitment in terms of advancing a new generation of tumor-selective medicines that are guided by the spatial biology of cancer. The former Flagship executive has in the past held roles at Novartis as well as AstraZeneca before joining InduPro in 2024.
This, apparently, is InduPro’s second deal with a large pharma announced publicly, with the first taking place in December. Sanofi, the French drugmaker, has also made an equity investment within the biotech and also inked a deal in order to fund as well as collaborate on the preclinical studies for bispecific PD-1 agonist antibodies. In return, the pharma has got the first pick of any of the successfully developed autoimmune candidates.
The lead autoimmune bispecific of InduPro, IDP-003, targets the PD-1 as well as T-cell antigen 2 and is presently in studies that are designed to help human testing. The biotech went on to raise $85 million in Series A funding in June 2024 and also works on many early programs in cancer.
